PharmTech Drug Digest 11.20
News|Articles|March 30, 2015

Rentschler Commissions 2000-L Single-Use Bioreactor

Rentschler Biotechnologie launches 2000-L single-use bioreactor and announces additional expansion.

 

Rentschler Biotechnologie, a contract manufacturing and development organization for biopharmaceuticals, announced on March 23 that the company’s 2000-L single-use bioreactor has been put into operation.

The bioreactor, built and commissioned in six months, doubles the company’s single-use manufacturing capabilities and integrates in the existing manufacturing suites by supplementing two existing 1000-L single-use bioreactors, according to a company statement.

Rentschler has more than five years’ experience with single-use bioreactors and features a facility with a flexible space concept and movable equipment.

Rentschler also announced that the company will invest €24 million to build a system with two 3,000-L stainless steel bioreactors.

Source: Rentschler Biotechnologie

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.